Psilocybin for Treatment-Resistant Depression: New Trial Results

For many people living with depression, the path to relief is not simple. Some try one antidepressant after another, add therapy, and still find that the heaviness never fully lifts. This is known as treatment-resistant depression (TRD), and it affects roughly one in three people with major depressive disorder.

A new randomized controlled trial, published in Nature Medicine in August 2026, offers real hope for this group. Researchers at King's College London and the South London and Maudsley NHS Foundation Trust found that a single dose of psilocybin, combined with psychological support, led to large and lasting improvements in depressive symptoms compared with placebo.

Why Treatment-Resistant Depression Needs New Options

Depression affects around 300 million people worldwide. When standard treatments don't work, the options become more specialized, such as ketamine, esketamine, electroconvulsive therapy, or transcranial magnetic stimulation. These can help, but access is often limited.

The participants in this trial had been living with depression for an average of 20 years. Unlike many commercially funded studies, the researchers did not set an upper limit on how treatment-resistant participants could be. That means the study included people who had tried many different treatments without success, which is a group that closely reflects real patients in real clinics.

Inside the Psilocybin-Assisted Therapy Trial

This was a double-blind, placebo-controlled trial. Sixty adults were randomly assigned to receive either 25 mg of psilocybin or a placebo. It was also, to the researchers' knowledge, the first trial of its kind to test this approach with a true placebo inside England's public health system, the NHS.

Every participant received the same careful, structured support:

• Preparation: Sessions with a trial therapist, including psychoeducation, before the dosing day.
• A guided dosing session: About six hours in a quiet, comfortable room with a therapist and chaperone, with optional eye mask and a curated music playlist.
• Integration: Follow-up sessions at one day, one week, three weeks, and six weeks after dosing to help participants process and make sense of their experience.

Key Findings: How Psilocybin Affected Depression Symptoms

The results were striking, and the improvement came quickly. The study measured depression with the Montgomery–Åsberg Depression Rating Scale (MADRS), a clinician-rated scale that runs from 0 to 60, where higher scores mean more severe depression and a score of 10 or below counts as remission. One week after dosing, the psilocybin group was already scoring about 11 points lower (better) than the placebo group on this scale. By the end of the six-week study, the gap was nearly 13 points. Differences of this size are considered clinically meaningful, meaning they reflect real changes in how people feel and function day to day.

Researchers also use a measure called “effect size” to show how big a difference between two groups is. By common standards, an effect size of 0.8 is considered large. At three weeks, this study found an effect size of 1.70, more than twice that threshold.

The numbers behind that improvement tell a hopeful story:

• Response rates: At three weeks, 43% of psilocybin participants had a strong clinical response, compared with just 3% on placebo. By week six, that rose to 50%.
• Remission: 40% of the psilocybin group reached remission at three weeks, meaning their depression scores had dropped to minimal levels. Only 3% of the placebo group did.
• Self-reported improvement: Half of psilocybin participants reported a meaningful response on their own depression questionnaire at week three. None in the placebo group did.
• Anxiety relief: At six weeks, only 17% of psilocybin participants reported moderate anxiety, compared with 62% of those on placebo.
• Daily functioning: Participants who received psilocybin reported being better able to manage work, home life, and social activities, with gains that grew from week three to week six.
• Broader wellbeing: The psilocybin group also improved in mental wellbeing, overall health rating, and core depression symptoms at every follow-up point.

These gains came after just one dosing session, in people who had struggled with depression for decades.

Psilocybin Side Effects Reported in the Trial

Psilocybin was well tolerated. Side effects were mostly mild and resolved by the end of the trial. Every serious adverse event in a participant who received psilocybin was judged unrelated to the treatment. Safety scales tracking suicidality and mania showed no concerning changes. On one measure of core depression symptoms, ratings related to suicidal thoughts actually improved in the psilocybin group.

The trial also succeeded at what it set out to test: whether a study like this could be run smoothly. Recruitment reached its target, every participant attended their dosing visit, and 59 out of 60 completed all follow-up assessments. That level of retention suggests the program was acceptable and meaningful to the people taking part.

What This Means for People With Treatment-Resistant Depression

This study marks an important milestone. It shows that psilocybin-assisted therapy can be delivered safely to patients with long-standing, hard-to-treat depression, and that it can produce meaningful relief after a single guided session.

For people who have tried everything and are still searching, research like this brings genuine reason for hope; psilocybin-assisted therapy is steadily moving closer to becoming a recognized, evidence-based option. It reinforces what many in the field have come to believe: with careful preparation, skilled support, and thoughtful integration, healing is possible even after years of struggle.

Read the Study: Rucker, J.J., Mantingh, T., Kerr-Gaffney, J. et al. Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nature Medicine 32, 3430–3437 (2026). https://www.nature.com/articles/s41591-026-04541-0